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Objective: The goal of this study is to better characterize the phenotypic heterogeneity
of oromandibular dystonia (OMD) for the purpose of facilitating early diagnosis.
Methods: First, we provide a comprehensive summary of the literature encompassing
1,121 cases. Next, we describe the clinical features of 727 OMD subjects enrolled by the
Dystonia Coalition (DC), an international multicenter cohort. Finally, we summarize clinical
features and treatment outcomes from cross-sectional analysis of 172 OMD subjects
from two expert centers.
Results: In all cohorts, typical age at onset was in the 50s and 70% of cases were
female. The Dystonia Coalition cohort revealed perioral musculature was involved most
commonly (85%), followed by jaw (61%) and tongue (17%). OMD more commonly
appeared as part of a segmental dystonia (43%), and less commonly focal (39%)
or generalized (10%). OMD was found to be associated with impaired quality of life,
independent of disease severity. On average, social anxiety (LSA score: 33 ± 28) was
more common than depression (BDI II score: 9.7 ± 7.8). In the expert center cohorts,
botulinum toxin injections improved symptom severity by more than 50% in ∼80% of
subjects, regardless of etiology.
Conclusions: This comprehensive description of OMD cases has revealed novel
insights into the most common OMD phenotypes, pattern of dystonia distribution,
associated psychiatric disturbances, and effect on QoL. We hope these findings will
improve clinical recognition to aid in timely diagnosis and inform treatment strategies.
Keywords: dystonia, jaw, tongue, treatment, botulinum (neuro)toxin
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INTRODUCTION

excluded due to diagnostic uncertainty. However, other acquired
forms of OMD (e.g., tardive syndromes) were included because
the majority of prior reports combined etiologies and it was
not feasible to reliably distinguish tardive from idiopathic
cases. Likewise, cases with task specific musician’s dystonia
were included because they were often described together
with idiopathic cases. For this review, OMD was defined as
dystonia affecting jaw, tongue and/or lower face. Bruxism has
mixed pathophysiology including mechanical alignment issues,
dental problems, disturbed sleep physiology, and peripheral
nervous system pathology (18). Subjects with bruxism were
only included if concurrently diagnosed with OMD. Subjects
with temporomandibular joint disorders who did not clearly
meet criteria for OMD were excluded (19, 20). Data extracted
from published case series included patient demographics and
dystonia etiology, clinical features, and treatment response. For
a subset of the literature for which case level data was available,
additional data was extracted on the frequency of phenotypic
subtypes (jaw opening, jaw closing, jaw deviation, tongue, and
face involvement).

Dystonia is a movement disorder characterized by sustained
or intermittent muscle contractions causing abnormal, often
repetitive movements, abnormal postures, or both (1). The
clinical presentations of oromandibular dystonia (OMD) include
varying combinations of abnormal jaw, tongue, or lower face
movements (2). OMD symptoms may be task specific, triggered
by speech or eating, or can be present at rest. OMD is particularly
disabling because it interferes with the ability to eat and speak,
and may be associated with marked discomfort.
Idiopathic focal OMD is rare, representing 3–5% of all
dystonias. Estimated incidence is 3.3/1,000,000 per year and
estimated prevalence is 68.9/1,000,000 (3). OMD is often
unrecognized, leading to a delay in diagnosis and treatment
(4, 5). The average time from onset of symptoms to diagnosis
in the most common forms of dystonia is 6 years, and this
delay is believed to be even longer in OMD (6, 7). Also due to
its rarity, much of our understanding is based on case reports
or relatively small series. Some of these focused on idiopathic
cases, others included acquired forms (8), and some included
a high representation of inherited disorders with OMD, such
as X-linked dystonia parkinsonism (9, 10). The descriptions
of OMD from these centers are quite varied. For example,
some expert centers recommend specific strategies for therapy
with Botulinum toxin (BoNT) (9, 11–13), while others do not
recommend it at all (14, 15). Some suggest that response of
tardive and idiopathic forms of OMD to BoNT is similar, but
large studies are lacking (16).
The purpose of this study is to better describe the clinical
heterogeneity of OMD using a three-tiered approach. First, we
provide a comprehensive summary of the largest prior studies
of OMD, encompassing 1,121 total cases in 27 separate reports.
Second, we describe the clinical features of OMD from the
Dystonia Coalition (DC), a methodical international multicenter
study of all types of dystonia (17), 727 of whom had OMD. Third,
we provide details on the treatment response of 172 cases from
two expert centers and investigate whether responses vary by
etiology. The collection of different types of information from
very different sources provides a comprehensive picture of this
very complex disorder. By providing a more comprehensive
description of OMD, we hope to improve clinical recognition to
facilitate timely diagnosis and treatment.

Dystonia Coalition Cohort
Data from the DC database were collected and analyzed
for 727 OMD subjects enrolled across 26 international sites
from 2011 to 2019 (http://clinicaltrials.gov/show/NCT01373424)
(17). To be included in the DC database subjects had to be
diagnosed with isolated dystonia of any type (focal, segmental,
multifocal, generalized). For the current study of OMD, subjects
were required to have dystonia in the jaw, tongue, and/or
perioral region. Exclusion criteria included any evidence of
acquired dystonia, significant medical or neurologic conditions
that preclude completing the examination, or other significant
condition that would confound diagnosis or evaluation. We
defined focal OMD as involvement of the lower face, jaw or
tongue. Segmental dystonia was diagnosed in subjects with
dystonia in contiguous body regions such as the upper face, neck,
or larynx.
Subjects completed a 26-item questionnaire describing
demographics and characteristics of their dystonia. A neurologist
specializing in movement disorders evaluated each participant
to determine distribution and severity of dystonia as measured
on the Global Dystonia Rating Scale (GDRS) (21). The GDRS
is a Likert-like scale with which dystonia is rated from 0
(absent) to 10 (maximum severity). Subjects were also queried
about any sensory trick (also known as geste antagoniste or
alleviating maneuver) (22) and prior treatments utilized. Clinical
features of interest included distribution of dystonia (focal,
segmental, general), areas affected (jaw, tongue, lower face), and
treatments utilized. Some subjects also completed the SF 36-Item
Health Survey assessing quality of life (QOL), Beck Depression
Inventory II scale (BDI), and Leibowitz Social Anxiety scale
(LSA). These data were collected only for subjects with onset <5
years to limit recall bias.

MATERIALS AND METHODS
Literature Review
The PubMed database was queried from January 1989 through
January 2021 for reports using the keywords “oromandibular
dystonia,” “jaw dystonia,” “Meige syndrome,” and “lingual
dystonia.” Other reports were found through the article
bibliographies. Only papers published in English with human
subject data were included. Case reports of <5 subjects
were excluded. Reviews that did not provide cohort or case
demographic or clinical data were excluded. Series that described
dystonia due to peripheral injury were excluded. Lower facial
twisting typical of functional (psychogenic) dystonia were
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Retrospective chart review identified a total 116 subjects
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from literature review are available by request from the
corresponding author.

evaluated at the Emory University Movement Disorders Clinic
(EMDC) between 2015 and 2019, and 56 subjects evaluated
in Head and Neck Surgical Group (HNSG) and the NY
Center for Voice and Swallowing Disorders, all of whom were
enrolled. EMDC is staffed by movement disorders neurologists,
whereas HNSG is staffed by otolaryngologists, capturing two
of the subspecialty fields that most commonly treat OMD.
The primary inclusion criterion was idiopathic or acquired
OMD, diagnosed as described previously. Exclusion criteria were
loss to follow up or other significant condition that would
confound diagnosis or treatment outcomes. Demographic and
clinical features including age at onset, sex, race, distribution of
dystonia, and areas affected were extracted from retrospective
chart review. Rating scale data, QOL, depression, and social
anxiety scores were not available for these subjects. However,
additional information was collected on BoNT treatment.

RESULTS
Review of Published Cases
A comprehensive literature query returned 27 papers meeting
inclusion criteria. These papers describe 1,121 cases including
idiopathic and acquired OMD (Table 1). The reports were
generally of single center cohorts for the purpose of defining
clinical features and treatment response. Only 6 described
cohorts >50 subjects. Among these series, 68% of subjects
were female and the mean age of onset was 52. Etiologies
varied by report, but primarily included idiopathic and tardive
cases. Although it is traditional to group OMD into specific
subtypes (jaw opening, jaw closing, tongue, lower face),
descriptions of clinical characteristics varied considerably, with
some authors defining each case by the predominant feature
and many describing a mixed picture. Among the 389 cases
described by the predominant feature, 45% were jaw closing,
31% jaw opening, 24% mixed, and 1% lingual. Only three
of 27 studies noted presence of lower facial or perioral
involvement, and none defined this as the predominant feature.
The majority of reports note that subjects received a trial
of BoNT. Variable measurements of response were used in
the literature, therefore Table 1 shows only the frequency of
cases reporting some level of response. Some centers did not
report on BoNT treatment and/or outcome, or treated some
subjects exclusively with oral pharmacotherapy. However, the
majority of reports describing BoNT note return for subsequent
injection and subjective improvement in symptoms and/or
QOL. No cases of OMD remission were described in the
manuscripts reviewed.

Data Analysis
Analyses were completed separately for each of the four cohorts
(Literature review, DC, EMDC, and HNSG) due to the different
types of data that were available for each. Although duplicate
reporting of the same case cannot be entirely excluded, every
effort was made to avoid including the same case more
than once. The literature review summarizes cases from very
different geographical locations, often from different countries,
and therefore is not likely to contain many duplicates. The
Dystonia Coalition tracks individual subjects and conducts DNA
fingerprinting, so enrollment of the same case more than once
can be identified and excluded. Patient identifiers were available
for the expert centers, so that duplicate reporting of the same case
could be definitively excluded.
Descriptive analyses for demographics and clinical
characteristics were completed. For the expert center cohorts
with detailed treatment data, additional descriptive analysis
was performed for therapies employed and response to
treatment. To evaluate whether treatment response varied
by etiology, ANOVA was utilized. Within the DC cohort,
additional descriptive analyses were performed for BDI, LSA,
and SF-36 scores. Univariate linear regression was performed to
estimate the association between QOL and demographic/clinical
characteristics. A multivariate linear regression model was
constructed accounting for age and sex, assessing QOL.
Distribution of dystonia (focal, segmental, hemidystonia, and
generalized) was also accounted for as a marker of severity. A
small amount of missing data was identified in the DC dataset
utilized for the regression analysis (<0.4%) and was treated as
missing at random. All data analysis was performed with SAS
version 9.4.
The study was approved by the internal review boards (IRBs)
of all participating clinical sites. All subjects gave written consent
for participation following the principles of the Declaration
of Helsinki.

DC Cohort
Table 2 presents a cross-sectional analysis of demographics and
clinical features for subjects with idiopathic OMD enrolled in
the DC database. Among the 727 cases, 70% were female and
the mean age at onset was 50 ± 16 (mean ± SD) years. In this
cohort, 87% of subjects identified as White. The distribution
of dystonia was most commonly segmental (43%), and less
commonly focal (39%) or generalized (10%). Sixty-one percent
had involvement of jaw, 85% had involvement of lower face, and
17% had involvement of tongue. GDRS severity scores averaged
3 ± 2, for the lower face 4 ± 2 for the jaw and tongue, with
average total scores of 16 ± 13. Among the subjects, 32% reported
having received BoNT treatment, but treatment details were
not available. Concurrent dystonia in other regions of the body
did not increase the chance that OMD patients received BoNT
therapy (p = 0.53).
Patient reported disability was measured by the SF-36
(Table 3), which was transformed such that a score of zero is
equivalent to maximum disability and a score of 100 is equivalent
to no disability. Average scores represent disability in all domains,
particularly in mental health (26 ± 20), physical role (50 ±
43), emotional role (50 ± 14), and vitality (53 ± 21). Mood
was evaluated with BDI, where total scores >13 are indicative

Data Availability
All data from the DC database are available by request from
the DC. Data on the expert center cohorts and extracted
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TABLE 1 | Clinical characteristics of 1,121 published cases of oromandibular dystonia.
References

n

Etiology

Clinical characteristics*

BoNT trial (n)

Percent of cases reporting
BoNT response**

Blitzer et al. (23)

20

NR+

NR

Yes (20)

95%

Jankovic et al. (24)

62

NR

JC (NR), JO (NR)

Yes (62)

73%

Hermanowicz and
Truong (25)

5

NR

JO (20%), JC (80%), L
(20%)

Yes (5)

100%

Van den Bergh et al. (26)

5

NR

JO (80%), L (20%)

Yes (5)

100%

Sankhla et al. (27)

21

NR

NR

Yes (21)

68%

Tan and Jankovic (28)

162

Idiopathic (63%), Tardive
(23%), Other (14%)

JO (22%), JC (53%),
M (24%)

Yes (162)

68%

Tan and Jankovic (16)

116

Idiopathic (79%)
Tardive (21%)

JO (23%), JC (49%), M
(28%), L (20%)

Yes (116)

100%

Bhattacharyya et al. (29)

5

NR

NR

Yes (5)

100%

Adler et al. (30)

5

Idiopathic (100%)

JO (40%), JC (40%), M
(20%)

Yes (5)

NR

Lo et al. (31)

5

Post-stroke (100%)

JC (100%)

Yes (5)

33%

Wan et al. (32)

12

NR

NR

Yes (12)

88%

Singer and
Papapetropoulos (33)

23

NR

JO (52%), JC (48%)

Yes (23)

65%

Lee (34)

6

NR

JC (50%), L (50%), P (67%)

Yes (2)

100%

Rosales et al. (9)

49

X-linked
dystonia-parkinsonism

JO (65%), JC (24%), M
(12%)

Yes (49)

100%

Merz et al. (35)

30

Idiopathic (83%)
Other (17%)

JO (10%), JC (23%), M
(33%), L (10%)

Yes (30)

100%

Esper et al. (8)

17

Idiopathic (47%)
Tardive (41%)
Degenerative (6%)
Post-infectious (6%)

JO (53%), JC (18%), M
(18%), L (100%)

Yes (9)

78%

Teive et al. (36)

5

Wilson’s disease (100%)

JO (100%)

Yes (5)

100%

Sinclair et al. (37)

59

Idiopathic (91%)
Tardive (9%)

JO (36%), JC (48%) M
(16%), L (17%)

Yes (59)

100%
NR

Bakke et al. (38)

21

NR

JO (19%), JC (5%), M (43%)

NR

Termsarasab et al. (14)

41

Idiopathic (100%)

M (63%), L (27%), P (5%)

Yes (18)

12%

Moscovich et al. (39)

8

NR

M (100%)

Yes (8)

100%

Teemul et al. (40)

6

Idiopathic (83%)
Tardive (17%)

M (100%)

Yes (6)

83%

Nastasi et al. (41)

30

Idiopathic (73%)
Tardive (13%)

JO (53%), JC (17%), M
(7%), L (100%), P (27%)

Yes (30)

87%

Kreisler et al. (42)

14

NR

JO (21%), JC (36%), M
(7%), P (29%)

Yes (7)

(All returned for repeat
injections)

Slaim et al. (43)

240

Idiopathic (71%) Tardive
(13%)
Other (16%)

JO (62%), JC (20%), M
(27%), L (27%)

No

NR

Scorr et al. (11)

18

Idiopathic (83%)
Tardive (17%)

JO (50%), JC (17%), M
(33%), L (33%),

Yes (18)

100%

Yoshida (12)

136

Tardive (31%)

M (20%), L (100%)

Yes (136)

NR

*Jaw Opening (JO), Jaw Closing (JC), Mixed Jaw Phenomenology (M), Lingual (L), Perioral (P).
reported (NR).
**Percentage does not indicate level of therapeutic effect, but percentage of cases reporting some therapeutic effect.
+ Not

Univariate linear regression revealed age, sex, distribution,
and severity of dystonia as measured by GDRS were not
significantly associated with total QOL score. Subjects identifying
as Black had QOL scores that were worse than subjects
identifying as White, indicating significantly worse physical QOL
(β = −10.25, p = 0.02). Mental QOL improved 0.34 points for

of depression (44). The average BDI score among subjects with
OMD was 9.7 ± 7.8, and 34% had scores indicative of depression.
Anxiety was assessed using the LSA score, where scores >30 are
consistent with social anxiety (45). The average LSA score among
subjects with OMD was 33 ± 28, and 44% had scores indicative
of social anxiety.
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TABLE 2 | Clinical characteristics and treatment response of oromandibular dystonia subjects in the Dystonia Coalition database, EMDC Cohort, and Head and Neck
Surgical Group (HNSG) Cohort.
Characteristics

Age of dystonia onset

Dystonia coalition
N = 727
n (%)/mean ± SD

EMDC Cohort
N = 116
n (%)/mean ± SD

HNSG Cohort
N = 56
n (%)/mean ± SD

50 ± 16

54 ± 15

50 ± 14

Focal

53 ± 12

59 ± 12

NR*

Segmental

50 ± 14

53 ± 14

NR

Generalized

26 ± 20

29 ± 22

NR

Male

217 (30%)

35 (30%)

7 (30%)

Female

510 (70%)

81 (70%)

49 (70%)
20 (36%)

Sex

Race
White

634 (87%)

76 (66%)

Black

57 (8%)

27 (23%)

2 (4%)

Other

30 (4%)

11 (9%)

4 (7%)

Unknown

6 (1%)

2 (2%)

30 (53%)

Etiology
Idiopathic

727 (100%)

75 (65%)

46 (82%)

Tardive

NR

25 (22%)

10 (18%)

Degenerative

NR

11 (9%)

NR

Stroke induced

NR

3 (2%)

NR

Genetic

NR

2 (2%)

NR

Focal

284 (39%)

53 (46%)

46 (82%)

Segmental

315 (43%)

57 (49%)

9 (16%)

Multifocal

46 (6%)

NR

NR

Hemi-dystonia

5 (1%)

NR

NR

74 (10%)

6 (5%)

1 (2%)

Lower face

620 (85%)

31 (29%)

3 (5%)

Jaw

440 (61%)

Distribution

Generalized
Areas affected

Opening

NR

40 (36%)

22 (39%)

Closing

NR

61 (56%)

12 (21%)

Deviation

NR

17 (16%)

2 (4%)

Mixed

NR

NR

20 (36%)

Tongue

123 (17%)

40 (36%)

7 (12%)

GDRS severity
Total

16 ± 13

NR

NR

Lower face

3±2

NR

NR

Jaw and tongue

4±2

NR

NR

BoNT
Treated

234 (32%)

115 (99%)

56 (100%)

Dose (Onabotulinum
toxin A equivalent units)

NR

102 (72)

73 (40)

EMG usage

NR

101 (88%)

NR

Good (75–100%)

NR

48 (45%)

48 (84%)

Moderate (50–74%)

NR

24 (23%)

3 (5%)

Partial (25–49%)

NR

2 (9%)

0

Minimal (1–24%)

NR

19 (18%)

1 (2%)

Not reported

NR

1 (1%)

4 (8%)

Toxin Response

*Not Reported (NR).
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TABLE 4 | Characteristics of remission in oromandibular dystonia cases.

TABLE 3 | Depression, anxiety, and QOL in oromandibular dystonia subjects
enrolled in the dystonia coalition natural history study.

Characteristics
Characteristics

Dystonia coalition natural
history study
N = 368
Mean ± SD

Age of dystonia onset

EMDC remission cases
N=9
N (%)/mean ± SD
55 ± 12

Sex
SF-36 sub-scores

Female

Physical function

71 ± 27

Role physical

50 ± 43

Body pain

63 ± 27

General health

62 ± 22

Vitality

53 ± 21

Social function

66 ± 29

Role emotional

50 ± 14

Mental health

26 ± 20

LSA score

33 ± 28

BDI score

10 ± 8

9 (100%)

Race
White

3 (33%)

Black

3 (33%)

Asian

1 (11%)

Unknown

2 (22%)

Etiology
Idiopathic

7 (78%)

Tardive

2 (22%)

Distribution
Focal

5 (56%)

Segmental

4 (44%)

Areas Affected
Jaw

each year older a patient was, indicating worse mental QOL for
younger subjects with OMD (β = 0.34, p < 0.01). GDRS severity
score was associated with worsened mental QOL, and each point
higher GDRS score was associated with a 0.6-point lower mental
component QOL score (β = −0.60, p < 0.01). Each point higher
on the BDI scale for depression was associated with a 1-point
lower mental and physical component QOL score (p < 0.01).
Each point higher on the LSA scale for anxiety was associated
with a 0.28-point and 0.14-point lower score for mental and
physical component QOL score, respectively (p < 0.01). Reported
exposure to BoNT therapy was not associated with QOL scores.
These findings underscore the negative effect of OMD on QOL as
well as the significance of comorbid depression and social anxiety
in this population.

Opening

0

Deviation

1 (11%)

Mixed

1 (11%)

Tongue

6 (67%)

BoNT
Treated
Dose (Onabotulinum
toxin A equivalent units)*
Duration of symptoms
(years)

9 (100%)
92 (86)
7±5

*Dose conversion ratio of AbobotulinumtoxinA to OnabotulinumtoxinA was 2.5:1.

Expert Center Cohorts

and diagnosis was 32 ± 35 months after onset. On average, 13 ±
10 BoNT sessions were provided prior to remission. The mean
dose used in the last visit prior to remission was 92 ± 86 units.
The mean duration of symptoms was 7 ± 5 years and mean
duration of remission was 20 ± 17 months at the time of chart
review. Seven subjects had idiopathic and two had tardive OMD.
Eight subjects had jaw opening dystonia, one patient had jaw
deviation and one case presented a mixed form (jaw opening and
jaw deviation). Lingual dystonia was present in six subjects.

Emory Movement Disorders Clinic
A retrospective analysis was performed for the cohort of 116
OMD subjects evaluated and treated at EMDC within the last
5 years, who were not already enrolled in the DC (Table 2).
Among these cases, 70% were female. The majority of subjects
had segmental (49%) and focal (46%) distributions, as compared
to generalized (5%). The most frequently affected area was jaw
(63%), though involvement of lower face (29%) and tongue
(36%) were common. The most common jaw movement was
closing (56%), followed by opening (36%), or deviation (17%).
Of the subjects seen at least twice, 99% received BoNT. The
average BoNT-A equivalent unit dosage was 102 ± 72 u. EMG
was used in 88% of cases to confirm injection placement. Routine
clinical practice at EMDC is to record improvement according
to percentiles, with 0% being no improvement and 100% being
complete relief of symptoms. Subjective improvement ranging
from 50 to 100% was reported by 68% of cases.
Among all cases, nine had remission (Table 4), all were
women. Three of these were White, three Black, one Asian, and
two of unknown race. The mean age at onset was 55 ± 12 years,

Frontiers in Neurology | www.frontiersin.org

8 (89%)

Closing

Head and Neck Surgical Group Cohort
A retrospective analysis was performed on 56 OMD subjects
evaluated at HNSG within the last 5 years (Table 2). Among these
cases, 70% were female. The majority had focal dystonia (82%),
as compared to segmental (15%) and generalized (2%). The most
common area affected was the jaw and presentations included jaw
opening (39%), jaw closing (21%), jaw deviation (4%), and mixed
phenomenology (36%). Additional lingual dystonia was present
in 13%. All subjects received BoNT and the average BoNT-A
equivalent dosage was 73 ± 40 u. Patients reported improvement
in pain and/or function as good in 84% of cases.
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Evaluation of Differences in Clinical Features and
Treatment Response by Etiology

women (50). Despite these similarities, each of the three sources
of information also provides novel insights into the varied nature
of OMD.

To evaluate whether clinical characteristics and BoNT treatment
response varied by etiology, the data from EMDC and the HNSG
were pooled for analysis. Etiology of OMD was categorized as
idiopathic, tardive, or other (degenerative, post-stroke, related
to a genetic syndrome such as Wilson’s disease or Pantothenate
kinase-associated neurodegeneration. Clinical characteristics and
treatment responses were investigated to determine whether they
were a function of etiology (Table 5). Demographic features
including age of onset and sex distribution did not vary
significantly by etiology. Features of lingual dystonia were more
common among tardive cases (p = 0.03), but there was no
significant difference in the occurrence of other phenomenology’s
by etiology. In contrast to previous reports (46, 47), total toxin
dose required (p = 0.78) and toxin response (p = 0.56) did not
vary by etiology.

Strengths and Weaknesses of Different
Sources
Combining data across very different sources is valuable for
identifying the most consistent findings. However, there also
are some limitations with including information from different
sources. One is the varied inclusion criteria and methods of
assessment and reporting make it difficult to merge all data into a
single analysis. Another weakness is the possibility of duplication,
as it is always difficult to be sure that some cases are not reported
more than once. For the literature review, this is unlikely,
because most of the reports come from geographically distant
areas, and often different countries. For the DC, a standard
procedure is used to prevent duplicate recruitment of cases. For
the expert centers, the availability of patient identifiers allowed
us to exclude any duplications, and we were careful to avoid any
subjects recruited by these centers for the Dystonia Coalition.
Additionally, although the amount of missing data was very
small (<0.4%), we cannot rule out that non-random patterns of
missingness in the DC data may have introduced some biases
(likely of small magnitude) in the results.
The literature provides the largest source of information on
OMD, with a total of 1,121 cases. However, the approach to
diagnosis and evaluation of OMD are also the most varied,
driven by varying habits used at different centers, and leading
to significant differences in findings. For example, some centers
reported mostly idiopathic OMD, while others focused on tardive
OMD or specific inherited subtypes such as X-linked dystoniaparkinsonism. Some centers described cases according to the

DISCUSSION
This study provides the largest and most comprehensive
summary of the phenotypic heterogeneity of OMD, to guide
improved recognition of this rare and particularly disabling
subtype of dystonia. It encompasses a total of 2,020 cases,
including 1,121 cases reported in the world’s literature, 727 new
cases from an international multicenter cohort, and 172 new
cases treated at 2 expert centers. Each of these three sources
of information regarding OMD has different strengths and
weaknesses. Despite the very different sources of information,
the overall results provide a remarkably consistent picture. Like
other focal dystonias, OMD tends to emerge in adults in the early
50s (48, 49). Like other focal dystonias, it is more common in

TABLE 5 | Variation in clinical characteristics and treatment response of oromandibular dystonia by etiology in expert center cases.
Characteristics

Age at dystonia onset

Idiopathic
N = 121
n (%)/mean ± SD

Tardive
N = 36
n (%)/mean ± SD

Other
N = 16
n (%)/mean ± SD

54 ± 13

54 ± 15

46 ± 23

Sex

p-value

0.97
0.54

Male

36 (30%)

9 (30%)

6 (40%)

Female

85 (70%)

27 (74%)

10 (60%)

33 (27%)

8 (21%)

3 (20%)

Opening

59 (49%)

14 (40%)

4 (26%)

0.15

Closing

64 (53%)

21 (57%)

13 (80%)

0.09

Deviation

17 (14%)

4 (11%)

1 (5%)

0.56

Tongue

33 (27%)

15 (43%)

2 (10%)

0.03

88 ± 64

73 ± 46

90 ± 75

0.48

5 (4%)

0

0

96 (79%)

27 (76%)

13 (80%)

Areas affected
Lower face

0.76

Jaw

BoNT
Dose (Onabotulinum
toxin A equivalent units)
Toxin response
None
>50% improvement
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Likert-like scales, or clinical impression. In the DC cohort where
severity was systematically assessed with the GDRS, total scores
were 16 ± 13, with much lower severity in the lower face (3 ± 2)
or jaw/tongue (4 ± 2). Despite the low GDRS scores for OMD,
the marked impact on QOL suggests that OMD is a particularly
disabling form of dystonia. This discrepancy suggests the GDRS
may not adequately capture OMD, perhaps because movements
of the jaw and tongue are difficult to see, and that routine use of
OMD-specific scales may be needed (52). Alternatively, it could
imply that non-motor features have a greater impact on QOL in
OMD, similar to other focal dystonias (53).
The DC included mostly idiopathic cases, while cases
from the literature and the two expert centers also included
acquired or combined dystonias. Nevertheless, overall results
were remarkably similar across these sources. Although some
reports suggest that dystonia in the jaw and tongue is a red flag
that should alert the clinician to an inherited metabolic disorder
such as neuroacanthocytosis or X-linked dystonia-parkinsonism
(47), results from the DC and expert centers indicate that OMD
is also, not uncommonly, the result of idiopathic and tardive
disease. It was possible to directly compare idiopathic and tardive
OMD for the expert centers, and the only difference involved
more significant tongue involvement in tardive cases.
A final area where there are significant differences in
the literature relates to treatment. Some studies argue the
response to oral therapy is strongest (14), while others
recommend BoNT (9, 11, 16, 28). Of 23 manuscripts reporting
treatment response, 11 reported 100% of cases improved, 10
reported >65% of cases improved, and only two reported
<50% of cases improved (Table 1). Review of data from
the expert centers provided more detailed information on
responses to BoNT. In both centers, most subjects were
treated with BoNT. Most reported >50% improvement. At
both centers, <10% of subjects reported no improvement.
Treatment responses were not significantly associated with
etiology with 79% of idiopathic and 76% of tardive OMD
patients reporting >50% improvement in symptoms. One
limitation of treatment data is that outcomes are retrospective
and based on subjective patient report, which is susceptible to
bias. Another limitation may be the heterogeneity of possible
pathogenic mechanisms among the cases analyzed, though
analysis by etiology did not reveal significant differences in
treatment response.
In addition to the many original reports of OMD summarized,
there have also been several reviews and commentaries focusing
on OMD (4, 5, 15, 54). Though these reviews focus on different
aspects of OMD, they also describe a picture consistent with our
report relating to age of onset, female predominance, and delayed
diagnosis due to poor recognition of the varied phenotypes
of OMD. Most experts agree that the varied phenotypes of
OMD represent a clinical syndrome arising from multiple
factors. A combination of genetic and environmental factors
are thought to combine to reach a threshold for manifestation
of clinical symptoms (54). Early symptoms of disease are
varied and may be subtle, which is believed to contribute to
delayed diagnosis may result in a higher actual prevalence than
previously reported (4). In an effort to address the problem

most affected region (tongue, jaw, lower face), while others
provided more details such as the type of jaw (e.g., closing,
opening, mixed) or tongue (e.g., protrusion, retraction, lateral
deviation) movements. Strategies and outcomes for treatment
were perhaps the most varied.
Data from the two expert centers provide new information
for a large number of new OMD cases (n = 172), along with
detailed information regarding treatment strategies. These data
also revealed several cases of long-lasting remissions, a novel
finding not apparent in the literature. Unlike with cervical
dystonia (51), remission in OMD occurred later in the disease
course, after mean disease duration of 6.9 years. The expert center
data were subject to some of the same limitations described for
the published literature. Both of these centers used somewhat
different approaches for diagnosis, evaluation, treatment, and
recording of treatment outcomes. Since the data from both
centers came from documentation regarding clinical care, certain
details were not always available, such as methodical assessment
of severity using rating scales, or detailed assessment of body
regions outside of the oromandibular region.
The data from the DC also provides new information for a
large number of OMD cases (n = 727). Since multiple centers
used the same protocols for evaluation, these data reflect the
most consistent information from the largest number of different
centers (17). These data also include quantitative rating scale
data for all body regions. Additionally, this cohort provided
novel insights into frequent psychiatric symptoms associated
with OMD, and their significant impact on QOL. However, the
DC included only isolated OMD, while the literature and expert
centers included mixed types of OMD. Further, the DC did
not collect data regarding treatment responses, or specific types
of movement abnormalities of the jaw (e.g., closing, opening,
mixed) or tongue (e.g., protrusion, retraction, lateral deviation).

Similarities and Differences Among
Different Sources
As noted above, the three sources of data provided remarkably
consistent information for certain features of OMD. They also
suggested some differences. For example, the literature described
most cases of OMD as a focal dystonia, although methods for
assessment of other body regions were not often reported (35).
On the other hand, data from the DC and one of the expert
centers suggest OMD is more often part of a broader segmental
pattern of dystonia. Similarly, involvement of the lower face is
uncommonly reported among cases in the literature, but very
common among cases in the DC, most likely because of the
methodical assessment of all body regions. Among studies that
focused on jaw dystonia, it seems likely there is a high probability
that less seriously affected regions like the lower face may not
be reported.
In addition to body distribution of dystonia, severity is also
an important aspect of OMD. Unfortunately, severity is difficult
to compare across the groups because of markedly different
methods used for assessment. Severity assessments included
clinician-rated dystonia scales, patient reported outcomes such
as the Oromandibular Dystonia Questionnaire (OMDQ-25) (35),
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of efficient diagnosis, a group of Italian Movement Disorder
experts formulated clinical diagnostic recommendations for
oromandibular dystonia. Their proposed clinical diagnostic
algorithm utilizes the consensus definition of dystonia and
leverages presence of sensory trick vs. atypical features to suggest
a diagnosis of OMD (5). Even when the diagnosis is certain,
a number of reviews and commentaries have debated the best
treatment strategy. Our study focused on BoNT treatments,
because they are the treatment of first choice for most focal
dystonias (55). Despite this, some have argued routine use cannot
be established in the absence of large controlled studies to
establish efficacy and safety (15). A hindrance to large clinical
trials has been the rarity of this disorder, but it is possible that
improved clinical recognition may make such trials more feasible.
Although a number of alternative treatments have been proposed
for OMD [e.g., pharmacotherapy, neurosurgical procedures
including deep brain stimulation (56), muscle afferent block
therapy, and acupuncture] (55), there were insufficient data
in the literature reviewed to compare the efficacy of these
alternative strategies. Further studies of treatment strategies
are warranted.

following the principles of the Declaration of Helsinki. The
patients/participants provided their written informed consent to
participate in this study.

CONCLUSIONS

FUNDING

Each tier of analysis in this study revealed novel insights
into the phenotypic heterogeneity of OMD. The frequency
of OMD presenting as a feature of segmental dystonia
underscores the importance of standardized clinical assessment
of cases for dystonia in other body regions. Assessment
may also benefit from utilization of disease specific rating
scales (52) to more accurately measure severity and capture
less prominent features, such as involvement of the perioral
lower facial musculature. Additionally, it may be important
to include screening for psychiatric disturbances, which were
found to be major determinants of QOL in this population.
Our findings suggest that BoNT injection is an effective
treatment for the majority of patients, regardless of etiology.
Prospective controlled trials may be useful to clarify the best
treatment strategies. Future directions also include investigating
the natural history of OMD to determine predictors of
progression or remission for this particularly disabling form
of dystonia.
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